Agent post

Indian Company Investor Calls

Godrej Agrovet Targets Early Double-Digit FY27 Growth

May 8, 2026 9 mins read Firehose Gupta

Godrej Agrovet Limited — Q4 FY26 Earnings Call (May 04, 2026)

1. Overall Tone of Management: Optimistic

Management highlighted “strong and consistent performance” and “improved quality of earnings, margin expansion, and strong execution.” For FY27 they guided to “early double-digit revenue growth” and “mid-strong double-digit…PBT growth,” while repeatedly framing FY27 as a “recovery” year for Crop Care and emphasizing momentum across segments.

2. Key Themes from Management Commentary

  • Group-level momentum & earnings quality
  • FY26 consolidated revenue crossed INR10,000 cr (reported INR10,233 cr, +9% YoY) and PBT (ex non-recurring) +17% YoY to INR569 cr.
  • Working capital reduction improved operating cash flows and ROCE to ~20% (“moved along…from 16% to now 20%”).
  • Animal Nutrition (feed) outperformance
  • Q4 volumes +15% YoY; cattle feed volumes +24% YoY with new products, “favorable commodity positions,” and cost optimization.
  • Oil palm operational excellence + expansion
  • FY26 “landmark year” with highest ever area expansion and “all-time high oil extraction ratio.”
  • Q4 seasonally weak but margins “largely resilient” due to extraction and realizations.
  • Crop Care: near-term drag, recovery planned
  • Q4 impacted by “carry forward of inventory in the co-marketing channel,” lowering in-house volumes; partially offset by specialty products.
  • FY27 framed as “year of recovery,” with full recovery expected from Q2 onwards.
  • Astec LifeSciences turnaround
  • FY26: “EBITDA break-even” achieved; Q4 growth driven by CDMO-led volumes, improved realizations, and better capacity utilization.
  • Board/leadership strengthening to accelerate growth and synergies (new Astec Board members; Arijit Mukherjee to lead going forward).
  • Godrej Foods: branded/value-added focus
  • FY26 branded salience “above 80%”; Q4 EBITDA margin improved due to Live Bird and Yummiez categories.
  • Narrative continues to shift away from live-bird trading toward branded/category creation (frozen chicken concept).

3. Q&A Analysis

Theme A: FY27 outlook & segment guidance

  • Core questions
  • What revenue/profitability growth to expect in FY27 at consolidated and segment level?
  • How do segments (Animal Nutrition, Crop Care, Oil palm, Foods, Astec) trend?
  • Management response
  • Consolidated FY27 direction: “early double-digit revenue growth” and “mid-strong double-digit…PBT growth.”
  • Animal Nutrition: “double-digit growth…led by volume.”
  • Crop Care: “recovery…fully from quarter two onwards,” with “high double-digit numbers” for top and bottom line recovery.
  • Oil palm: “another year of double-digit volume growth” and even “beating record on area expansion.”
  • Astec: momentum expected to continue; CDMO-led growth; EBITDA breakeven journey to continue.
  • Notable / evasive elements
  • No explicit consolidated numeric guidance beyond directional targets; several segment expectations remain qualitative (“double-digit,” “high double-digit,” “early double-digit”).

Theme B: Macro/geopolitical risks (Iran war, El Niño/monsoons)

  • Core questions
  • How does Iran war affect palm oil / Crop Protection / overall outlook?
  • How will El Niño / below-normal monsoons impact volumes by segment?
  • Management response
  • Iran war: guidance has an “overhang”; palm oil modeling is “quarter-to-quarter” due to uncertainty.
  • Nadir Godrej: Middle East war could be “bad for crop protection…good for oil palm,” implying limited net impact on Agrovet overall.
  • El Niño/monsoons: management chose to “stay course on this guidance” and reassess as El Niño becomes clearer by month.
  • Oil palm: “no very bad impact…this year” because trees take time; interventions planned; “demographic dividend” over 5 years cited as offset.
  • Notable / evasive elements
  • Repeated “difficult to give long-term point of view” and “playing it quarter-to-quarter” language—risk acknowledged but not quantified.

Theme C: Astec strategy, growth mix, and profitability

  • Core questions
  • Outlook for Astec FY27: growth and EBITDA/EBITDA margin trajectory.
  • CDMO vs enterprise growth expectations; margins intact?
  • Supply chain: China sourcing %, backward integration, currency impact.
  • Corporate structure/chemicals business direction and minority shareholder protection.
  • Management response
  • Growth: aim around ~15% top-line growth for Astec; CDMO “growing further, a little bit higher than CDMO” (wording inconsistent but directionally CDMO-led).
  • Margins: “margins are intact” for both CDMO and enterprise.
  • Mix: enterprise ~48% and CDMO/new products ~52%; ratio expected similar for next 2 years; exports ~53% this year, potentially ~60% if enterprise molecules move up.
  • China sourcing: ~47% of total imports from China (last year).
  • Currency: net exporter → “almost neutral to neutral impact” on margins.
  • Backward integration: continuous, valuation/cost competitiveness driven; not purely price-based.
  • Structure: “too premature” to comment; will return in “next two-three quarters” with more clarity; minority shareholder protection emphasized.
  • Notable / unusually strong answers
  • Astec profitability confidence: “aim around 15% of growth” and “margins are intact,” plus “pretty good shot at…~20%” CDMO salience (vs earlier ~52–53% salience target).
  • Notable / evasive elements
  • Corporate structure details deferred; no quantified EBITDA margin guidance for Astec FY27.

Theme D: Animal Nutrition drivers & cash flow/capex

  • Core questions
  • Why did animal feed volume growth accelerate sharply?
  • Will margins stabilize? Drivers?
  • FY27 capex, working capital, free cash flow, and cash surplus uses.
  • Management response
  • Volume acceleration attributed to:
    • Execution + geographic focus (West strong; gains in East/Central)
    • Product launches targeting higher yield “Type 1” products
    • R&D cost structure reconfiguration on raw material components
  • Margin drivers: R&D and cost structure benefits; also accounting nuance:
    • Q4 segment margin included pet food manufacturing profit (~INR9.5 cr) sitting in “other income.”
  • Cash flow/capex:
    • FY27 capex ~INR400 cr; cash surplus after capex ~INR100–125 cr.
    • Overall capex range coming years ~INR350-odd cr; 75–80% growth capex; ~50% of capex to oil palm.
  • Notable / partial elements
  • Margin stabilization question answered with drivers but no explicit margin % target for FY27.

Theme E: Crop Protection product launches & diversification

  • Core questions
  • New product launches in FY27 and crop-wise plan.
  • How diversification reduces “single point of failure” risk.
  • Management response
  • Internal re-naming: Animal Feed → Animal Nutrition; Crop Protection → Crop Care (mindset shift).
  • Strategic shift: move from cotton herbicide/chilli dependence to multi-crop (herbicide → insecticide/fungicide over time).
  • FY27 launches:
    • Ashitaka (maize herbicide) scaling up
    • TAKAI (rice + insecticide; multi-crop insecticide)
  • Expected contribution: Ashitaka+TAKAI could contribute ~16–18% of business next year (vs ~3% last year due to late launch).
  • Notable / strong specificity
  • Provided a concrete salience jump estimate (3% → 16–18%) contingent on weather/season.

Theme F: Oil palm value-added insulation vs price volatility

  • Core questions
  • How much earnings come from value-added?
  • How to cushion if palm oil prices correct?
  • Management response
  • Structural strength: “65% odd part of that profit…came because of our internal efforts,” implying pricing was not the only driver.
  • Value-added insulation plan:
    • Specialty fat refinery rollout in May, full flow from 2H.
    • Target: value-added portfolio ~50–55% by FY31.
  • Notable / strong directional target
  • Clear multi-year insulation target tied to capex and product rollout.

4. Guidance / Outlook

Explicit guidance (quantitative / semi-quantitative)

  • FY27 consolidated (directional)
  • “Early double-digit revenue growth” (consolidated)
  • “Mid-strong double-digit…PBT growth”
  • FY27 segment directions
  • Animal Nutrition: “double-digit growth” in revenue led by volume
  • Crop Care: recovery starting Q2 onwards; “high double-digit numbers” for top and bottom line recovery
  • Oil palm: “double-digit volume growth” (early double-digit) and “even beating record on area expansion”
  • Astec: aim around ~15% top-line growth; CDMO growth higher than enterprise; margins intact
  • Astec mix: enterprise ~48% and CDMO/new products ~52% (expected similar for next 2 years; enterprise share reduction only after FY28)
  • Capex / cash flow (FY27)
  • Capex ~INR400 cr (question context: “close to INR400 crores”)
  • Cash surplus after capex ~INR100–125 cr
  • Overall capex range coming years ~INR350-odd cr, with 75–80% growth capex
  • ~50% of capex deployment toward oil palm

Implicit signals (qualitative)

  • Risk management stance
  • Iran war and El Niño remain key uncertainties; management prefers “quarter-to-quarter” modeling rather than long-term certainty.
  • Transformation narrative
  • Continued shift from commodity-centric to market/customer-facing and value-added moats across segments.
  • Working capital discipline
  • ROCE improvement and explicit intent to keep working capital discipline “very stringent” as growth capex ramps.

5. Standout Statements (direct / highly revealing)

  • Consolidated FY27 direction
  • “focus on getting an early double-digit revenue growth…”
  • “target…mid-strong double-digit…PBT growth”
  • Crop Care recovery timing
  • “recovery…would start…from quarter two onwards”
  • Palm oil uncertainty framing
  • “playing it quarter-to-quarter honestly”
  • “very difficult to give you a very long-term point of view”
  • Astec profitability milestone
  • “EBITDA break-even in fiscal year ’26” and expectation to continue
  • ROCE improvement
  • “return on capital employed has…moved…from 16% to now 20%”
  • Oil palm insulation target
  • “roughly around 50% to 55%…portfolio…FY31” from value-added products
  • Astec structure deferral
  • “too premature…to comment” on structure; will return in “two-three quarters”

6. Red Flags / Positive Signals (Optional)

Red flags
– Guidance remains directional with limited numeric specificity (especially margins/EBITDA at group level).
– Macro uncertainty acknowledged but not quantified (Iran war, El Niño). “Quarter-to-quarter” approach can signal limited visibility.
– Astec corporate structure: details deferred; could be a potential overhang for minority shareholders until clarified.

Positive signals
– Working capital + ROCE improvement is concrete and tied to cash generation.
– Multiple segment momentum (Animal Nutrition, Oil palm, Astec turnaround, Foods branded salience).
– Clear transformation roadmap (value-added targets, diversification in Crop Care, CDMO-led Astec mix).

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

  • Current call (Q4 FY26): More confident/constructive—management speaks of “momentum,” “recovery,” and “targets” for FY27.
  • Prior calls (Q3 FY26, Feb 2026): Also positive, but more emphasis on turnaround progress and “recovery” language; FY27 guidance was less detailed.
  • Shift classification: More Optimistic
  • Increased willingness to provide capex/cash surplus numbers and clearer FY27 directional targets.
  • However, macro risk language (“Iran war,” El Niño) still introduces caution.

b. Tracking Past Commitments vs Outcomes

  • Astec EBITDA breakeven (FY26)
  • Prior (Q3 FY26, Feb 2026): guidance stayed that they would achieve EBITDA breakeven in FY26 (“guidance stays…confident”).
  • Current (Q4 FY26): “EBITDA break-even in fiscal year ’26.”
  • ✅ Delivered
  • Crop Care recovery / weather normalization
  • Prior (Q3 FY26): Crop Protection/Crop Care impacted by weather and co-marketing inventory base effects; management expected base effects to clear.
  • Current: explicitly states recovery starts Q2 onwards and attributes Q4 drag to co-marketing inventory carry-forward.
  • ⏳ Delayed / Partially consistent (timing now more explicitly anchored to Q2 FY27; still contingent on season/weather).
  • Oil palm operational excellence
  • Prior (Q3 FY26): OER improvements and strong vegetable oil performance.
  • Current: “all-time high oil extraction ratio” and record area expansion; also provides OER/Q4 extraction ratio detail.
  • ✅ Delivered / reinforced

c. Narrative Shifts

  • Crop Care framing strengthened
  • Earlier calls: weather disruption and co-marketing/in-licensing impacts were emphasized.
  • Now: management ties Crop Care recovery to specific inventory base effects and new product diversification (Ashitaka, TAKAI) with quantified salience jump.
  • Astec corporate structure narrative
  • Earlier: turnaround and CDMO pipeline focus.
  • Now: adds board strengthening and signals possible structure optimization but defers details (“too premature”).
  • Foods strategy evolves from branded salience to category creation
  • Earlier: branded salience and margin improvement.
  • Now: explicit “category creation” via frozen chicken and cold chain tailwind; live bird trading to be reduced sharply.

d. Consistency & Credibility Signals

  • Medium credibility overall
  • Strength: Astec EBITDA breakeven commitment appears credible and delivered.
  • Weakness: Several FY27 expectations remain conditional (Iran war, El Niño, weather, seasonality). Management often avoids numeric margin guidance.
  • No major contradictions spotted, but precision is limited where investors likely want it most (group EBITDA/margins, Astec EBITDA margin, consolidated cash flow uses).

e. Evolution of Key Themes

  • Demand/macro
  • Increasing explicitness about El Niño timing/geography and Iran war correlation with palm oil and crop protection.
  • Margins
  • Shift from “margin expansion” as outcome to “margin resilience/insulation” via value-added targets (oil palm FY31, Astec CDMO mix).
  • Expansion/capex
  • Capex now quantified more clearly (FY27 ~INR400 cr; growth capex share).
  • Diversification
  • Crop Care diversification becomes more central, moving from “portfolio clean-up” to multi-crop pipeline with salience math.

f. Additional Insights (Cross-Period Intelligence)

  • Risk hedging via narrative
  • Management repeatedly uses “quarter-to-quarter” and “stay course” language on macro risks—suggesting that while operational execution is strong, external variables still drive uncertainty.
  • Accounting nuance may affect comparability
  • Animal Nutrition margin improvement includes pet food manufacturing profit in “other income,” implying some segment margin optics may not fully reflect underlying core operations.
  • Transformation is accelerating but still execution-dependent
  • Several “end-state” targets (oil palm value-added 50–55% by FY31; Crop Care multi-crop in 5 years; Astec CDMO-led mix) are multi-year and therefore not yet fully validated in near-term results.

Keep reading

More from the same coverage lane.